Table 1 Comparable demographics and clinical characteristics of multicentre (n = 497) and single-centre (n = 181) systemic sclerosis cohorts
From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Multicentre cohort n = 497 (243 diffuse) | Single-centre cohort* n = 181 (83 diffuse) | |
|---|---|---|
Age (years) | 59.7 ± 13.9 | 55.8 ± 14.6 |
Diffuse | 58.5 ± 14.2 | 54.3 ± 13.9 |
Limited | 60.6 ± 13.8 | 56.8 ± 15.2 |
Gender (women) | 438 (88%) | 161 (89%) |
Diffuse | 213 (88%) | 75 (91%) |
Limited | 225 (89%) | 86 (86%) |
Disease duration (years) | 11.8 ± 8.4 | 11.8 ± 8.3 |
Diffuse | 12.4 ± 8.0 | 11.9 ± 7.8 |
Limited | 11.2 ± 8.4 | 11.9 ± 8.6 |
Arthritis | 298 (60%) | 114 (63%) |
Diffuse | 156 (64%) | 58 (70%) |
Limited | 142 (56%) | 56 (57%) |
Pulmonary fibrosis | 308 (62%) | 119 (66%) |
Diffuse | 190 (78%) | 66 (80%) |
Limited | 118 (46%) | 53 (54%) |
Pulmonary hypertension | 54 (11%) | 18 (10%) |
Diffuse | 30 (12%) | 9 (11%) |
Limited | 24 10%) | 9 (10%) |
Cardiac rhythm disorders | 68 (14%) | 24 (13%) |
Diffuse | 40 (16%) | 13 (15%) |
Limited | 28 (11%) | 11 (11%) |
Renal crisis | 9 (2%) | 5 (3%) |
Diffuse | 6 (2%) | 3 (3%) |
Limited | 3 (1%) | 2 (2%) |
Digital ulcers | 268 (54%) | 96 (53%) |
Diffuse | 168 (69%) | 53 (64%) |
Limited | 100 (39%) | 43 (44%) |
Upper gastrointestinal involvement | 363 (73%) | 136 (75%) |
Diffuse | 207 (85%) | 67 (83%) |
Limited | 156 (61%) | 66 (68%) |